Donna E. Hansel MD PhDProfessor, UCSD Department of PathologyChief, Division of Anatomic Pathology9500 Gilman Drive, MC 0612La Jolla, CA 92093Seth P. Lerner, MD, FACSProfessor, Scott Department of UrologyBeth and Dave Swalm Chair in Urologic Oncology Director of Urologic OncologyDirector of the Multidisciplinary Bladder Cancer ProgramFaculty Group Practice Medical Director Co-Editor in Chief Bladder CancerBaylor College of Medicine Medical Center7200 Cambridge, MC BCM380 Houston, Texas  77030

• 1.Risk Factors and Molecular Features Associated with Bladder Cancer Development.- 2.Grading, Staging, and Morphologic Risk Stratification of Bladder Cancer.-  3.Genomic Assessment of Muscle-Invasive Bladder Cancer: Insights from The Cancer Genome Atlas (TCGA) Project.-  4.Molecular Alterations in the Pathogenesis of Bladder Cancer Subtypes and Urothelial Carcinoma Variants.- 5.Treatment Paradigms in Bladder Cancer: Clinical Implications of Histological and Molecular Analysis.- 6.Requisite for Collection and Distribution of Tissue and Fluid Specimens for Molecular Diagnostics and Discovery in Bladder Cancer.-  7.Diagnostic, Prognostic and Predictive Biomarkers on Bladder Tissue and Blood.- 8.Urine Cytology and Existing Urinary Biomarkers for Bladder Cancer.- 9.Molecular Targeted Therapy of Bladder Cancer.- 10.Response to Immunotherapy: Application of Molecular Pathology to Predict Successful Response.- 11.Emerging Molecular Approaches in the Analysis of Urine in Bladder Cancer Diagnosis.- 12. Stromal Contributions to Tumor Progression in Urothelial  Carcinoma of the Bladder.- 13.Modeling Bladder Cancer with Genetic Engineering: Fidelity of Human-to-laboratory Models.

Donna E. Hansel MD PhDProfessor, UCSD Department of PathologyChief, Division of Anatomic Pathology9500 Gilman Drive, MC 0612La Jolla, CA 92093Seth P. Lerner, MD, FACSProfessor, Scott Department of UrologyBeth and Dave Swalm Chair in Urologic Oncology Director of Urologic OncologyDirector of the Multidisciplinary Bladder Cancer ProgramFaculty Group Practice Medical Director Co-Editor in Chief Bladder CancerBaylor College of Medicine Medical Center7200 Cambridge, MC BCM380 Houston, Texas  77030

• 1.Risk Factors and Molecular Features Associated with Bladder Cancer Development.- 2.Grading, Staging, and Morphologic Risk Stratification of Bladder Cancer.-  3.Genomic Assessment of Muscle-Invasive Bladder Cancer: Insights from The Cancer Genome Atlas (TCGA) Project.-  4.Molecular Alterations in the Pathogenesis of Bladder Cancer Subtypes and Urothelial Carcinoma Variants.- 5.Treatment Paradigms in Bladder Cancer: Clinical Implications of Histological and Molecular Analysis.- 6.Requisite for Collection and Distribution of Tissue and Fluid Specimens for Molecular Diagnostics and Discovery in Bladder Cancer.-  7.Diagnostic, Prognostic and Predictive Biomarkers on Bladder Tissue and Blood.- 8.Urine Cytology and Existing Urinary Biomarkers for Bladder Cancer.- 9.Molecular Targeted Therapy of Bladder Cancer.- 10.Response to Immunotherapy: Application of Molecular Pathology to Predict Successful Response.- 11.Emerging Molecular Approaches in the Analysis of Urine in Bladder Cancer Diagnosis.- 12. Stromal Contributions to Tumor Progression in Urothelial  Carcinoma of the Bladder.- 13.Modeling Bladder Cancer with Genetic Engineering: Fidelity of Human-to-laboratory Models.

Donna E. Hansel MD PhDProfessor, UCSD Department of PathologyChief, Division of Anatomic Pathology9500 Gilman Drive, MC 0612La Jolla, CA 92093Seth P. Lerner, MD, FACSProfessor, Scott Department of UrologyBeth and Dave Swalm Chair in Urologic Oncology Director of Urologic OncologyDirector of the Multidisciplinary Bladder Cancer ProgramFaculty Group Practice Medical Director Co-Editor in Chief Bladder CancerBaylor College of Medicine Medical Center7200 Cambridge, MC BCM380 Houston, Texas  77030

• 1.Risk Factors and Molecular Features Associated with Bladder Cancer Development.- 2.Grading, Staging, and Morphologic Risk Stratification of Bladder Cancer.-  3.Genomic Assessment of Muscle-Invasive Bladder Cancer: Insights from The Cancer Genome Atlas (TCGA) Project.-  4.Molecular Alterations in the Pathogenesis of Bladder Cancer Subtypes and Urothelial Carcinoma Variants.- 5.Treatment Paradigms in Bladder Cancer: Clinical Implications of Histological and Molecular Analysis.- 6.Requisite for Collection and Distribution of Tissue and Fluid Specimens for Molecular Diagnostics and Discovery in Bladder Cancer.-  7.Diagnostic, Prognostic and Predictive Biomarkers on Bladder Tissue and Blood.- 8.Urine Cytology and Existing Urinary Biomarkers for Bladder Cancer.- 9.Molecular Targeted Therapy of Bladder Cancer.- 10.Response to Immunotherapy: Application of Molecular Pathology to Predict Successful Response.- 11.Emerging Molecular Approaches in the Analysis of Urine in Bladder Cancer Diagnosis.- 12. Stromal Contributions to Tumor Progression in Urothelial  Carcinoma of the Bladder.- 13.Modeling Bladder Cancer with Genetic Engineering: Fidelity of Human-to-laboratory Models.